Literature DB >> 19147580

Chromosomal signatures of a subset of high-grade premalignant cervical lesions closely resemble invasive carcinomas.

Saskia M Wilting1, Renske D M Steenbergen, Marianne Tijssen, Wessel N van Wieringen, Theo J M Helmerhorst, Folkert J van Kemenade, Maaike C G Bleeker, Mark A van de Wiel, Beatriz Carvalho, Gerrit A Meijer, Bauke Ylstra, Chris J L M Meijer, Peter J F Snijders.   

Abstract

Cervical cancer develops from precancerous high-grade cervical intraepithelial neoplasia (CIN) harboring a transforming infection with high-risk human papillomavirus, which is characterized by p16(INK4a) overexpression. Once such a lesion has developed, progression toward an invasive squamous cell carcinoma (SCC) may take one or more decades, underlining the heterogeneity of these lesions in terms of duration of existence and progression risk. We performed array-based comparative genomic hybridization (array CGH) on 46 p16(INK4a) immunopositive CIN2/3 lesions to determine whether this heterogeneity is reflected in their chromosomal profiles. Chromosomal profiles of CIN2/3 lesions were related to those of invasive cervical SCC and promoter methylation of CADM1, a tumor suppressor gene known to be functionally involved in the tumorigenic phenotype of cervical cancer cells. Frequent alterations found in CIN2/3 lesions included gains located at chromosome 1, 3, 7, and 20 and losses located at 4, 11, 16, 17, and 19. Unsupervised hierarchical clustering identified two subsets of CIN2/3 lesions, chromosomal profiles of one of which closely resembled invasive SCCs. Gains of 1, 3q, and 20 were characteristic for CIN2/3 lesions with chromosomal signatures resembling carcinomas. In addition, dense promoter methylation of the CADM1 gene was significantly more frequent in these CIN2/3 lesions (P = 0.004). No chromosomal alterations were detected in six CIN1 lesions, five of which were completely p16(INK4a) immunonegative. These findings suggest that biomarkers associated with gains at chromosomes 1, 3q, and 20 are potential hallmarks of advanced p16(INK4a)-positive CIN2/3 lesions with a high short-term risk of progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19147580     DOI: 10.1158/0008-5472.CAN-08-2478

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  ZBRK1 acts as a metastatic suppressor by directly regulating MMP9 in cervical cancer.

Authors:  Li-Fang Lin; Chih-Hung Chuang; Chien-Feng Li; Ching-Chun Liao; Chun-Pei Cheng; Tian-Lu Cheng; Meng-Ru Shen; Joseph T Tseng; Wen-Chang Chang; Wen-Hwa Lee; Ju-Ming Wang
Journal:  Cancer Res       Date:  2009-12-08       Impact factor: 12.701

2.  Epigenetic silencing of a proapoptotic cell adhesion molecule, the immunoglobulin superfamily member IGSF4, by promoter CpG methylation protects Hodgkin lymphoma cells from apoptosis.

Authors:  Paul G Murray; Yichao Fan; Gillian Davies; Jianming Ying; Hua Geng; Ka Man Ng; Hongyu Li; Zifen Gao; Wenbin Wei; Shikha Bose; Jennifer Anderton; Georgia Kapatai; Gary Reynolds; Akihiko Ito; Teresa Marafioti; Ciaran Bj Woodman; Richard Ambinder; Qian Tao
Journal:  Am J Pathol       Date:  2010-08-13       Impact factor: 4.307

Review 3.  Integrative genomic approaches in cervical cancer: implications for molecular pathogenesis.

Authors:  Gopeshwar Narayan; Vundavalli V Murty
Journal:  Future Oncol       Date:  2010-10       Impact factor: 3.404

4.  SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas.

Authors:  Thomas Hussenet; Soraya Dali; Julien Exinger; Ben Monga; Bernard Jost; Doulaye Dembelé; Nadine Martinet; Christelle Thibault; Joerg Huelsken; Elisabeth Brambilla; Stanislas du Manoir
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

5.  Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results.

Authors:  Patricia Luhn; Jane Houldsworth; Lynnette Cahill; Mark Schiffman; Philip E Castle; Rosemary E Zuna; S Terence Dunn; Michael A Gold; Joan Walker; Nicolas Wentzensen
Journal:  Gynecol Oncol       Date:  2013-06-13       Impact factor: 5.482

6.  Genome-wide screening of DNA copy number alterations in cervical carcinoma patients with CGH+SNP microarrays and HPV-FISH.

Authors:  Petr Kuglik; Jan Smetana; Vladimira Vallova; Lucie Moukova; Katerina Kasikova; Michaela Cvanova; Lucie Brozova
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

7.  HPV type-related chromosomal profiles in high-grade cervical intraepithelial neoplasia.

Authors:  Mariska Bierkens; Saskia M Wilting; Wessel N van Wieringen; Mark A van de Wiel; Bauke Ylstra; Chris J L M Meijer; Peter J F Snijders; Renske D M Steenbergen
Journal:  BMC Cancer       Date:  2012-01-24       Impact factor: 4.430

8.  Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer.

Authors:  Malin Lando; Marit Holden; Linn C Bergersen; Debbie H Svendsrud; Trond Stokke; Kolbein Sundfør; Ingrid K Glad; Gunnar B Kristensen; Heidi Lyng
Journal:  PLoS Genet       Date:  2009-11-13       Impact factor: 5.917

9.  Cancer Risk Stratification of Anal Intraepithelial Neoplasia in Human Immunodeficiency Virus-Positive Men by Validated Methylation Markers Associated With Progression to Cancer.

Authors:  Ramon P van der Zee; Olivier Richel; Carel J M van Noesel; Iuliana Ciocănea-Teodorescu; Annina P van Splunter; Timo J Ter Braak; Mayura Nathan; Tamzin Cuming; Michael Sheaff; Alexander Kreuter; Chris J L M Meijer; Wim G V Quint; Henry J C de Vries; Jan M Prins; Renske D M Steenbergen
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

10.  5-bp Classical Satellite DNA Loci from Chromosome-1 Instability in Cervical Neoplasia Detected by DNA Breakage Detection/Fluorescence in Situ Hybridization (DBD-FISH).

Authors:  Elva I Cortés-Gutiérrez; Brenda L Ortíz-Hernández; Martha I Dávila-Rodríguez; Ricardo M Cerda-Flores; José Luis Fernández; Carmen López-Fernández; Jaime Gosálvez
Journal:  Int J Mol Sci       Date:  2013-02-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.